Primary diagnosis for patients with potential clinically serious pulmonary adverse events
| . | Treatment group . | Total, N (%) . | |
|---|---|---|---|
| Test, N (%) . | Reference, N (%) . | ||
| Total patients | 78 (100) | 70 (100) | 148 (100) |
| Hematologic malignancy | 74 (94.9) | 64 (91.4) | 138 (93.2) |
| Acute leukemia | 31 (39.7) | 25 (35.7) | 56 (37.8) |
| ALL | 6 (7.7) | 5 (7.1) | 11 (7.4) |
| ANLL/AML | 25 (32.1) | 20 (28.6) | 45 (30.4) |
| Chronic leukemia/HCL | 11 (14.1) | 11 (15.7) | 22 (14.9) |
| CML | 7 (9.0) | 7 (10.0) | 14 (9.5) |
| CLL | 3 (3.8) | 3 (4.3) | 6 (4.1) |
| CMML | 1 (1.3) | 1 (1.4) | 2 (1.4) |
| HCL | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Lymphoma | 12 (15.4) | 20 (28.6) | 32 (21.6) |
| NonHodgkin | 12 (15.4) | 20 (28.6) | 32 (21.6) |
| Hodgkin | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Myelodysplasia | 5 (6.4) | 1 (1.4) | 6 (4.1) |
| Plasma cell dyscrasia | 15 (19.2) | 7 (10.0) | 22 (14.9) |
| Myeloma | 15 (19.2) | 6 (8.6) | 21 (14.2) |
| Other | 0 (0.0) | 1 (1.4) | 1 (0.7) |
| Solid tumor | 2 (2.6) | 3 (4.3) | 5 (3.4) |
| Carcinoma | 2 (2.6) | 3 (4.3) | 5 (3.4) |
| Sarcoma | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Other diseases* | 2 (2.6) | 3 (4.3) | 5 (3.4) |
| . | Treatment group . | Total, N (%) . | |
|---|---|---|---|
| Test, N (%) . | Reference, N (%) . | ||
| Total patients | 78 (100) | 70 (100) | 148 (100) |
| Hematologic malignancy | 74 (94.9) | 64 (91.4) | 138 (93.2) |
| Acute leukemia | 31 (39.7) | 25 (35.7) | 56 (37.8) |
| ALL | 6 (7.7) | 5 (7.1) | 11 (7.4) |
| ANLL/AML | 25 (32.1) | 20 (28.6) | 45 (30.4) |
| Chronic leukemia/HCL | 11 (14.1) | 11 (15.7) | 22 (14.9) |
| CML | 7 (9.0) | 7 (10.0) | 14 (9.5) |
| CLL | 3 (3.8) | 3 (4.3) | 6 (4.1) |
| CMML | 1 (1.3) | 1 (1.4) | 2 (1.4) |
| HCL | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Lymphoma | 12 (15.4) | 20 (28.6) | 32 (21.6) |
| NonHodgkin | 12 (15.4) | 20 (28.6) | 32 (21.6) |
| Hodgkin | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Myelodysplasia | 5 (6.4) | 1 (1.4) | 6 (4.1) |
| Plasma cell dyscrasia | 15 (19.2) | 7 (10.0) | 22 (14.9) |
| Myeloma | 15 (19.2) | 6 (8.6) | 21 (14.2) |
| Other | 0 (0.0) | 1 (1.4) | 1 (0.7) |
| Solid tumor | 2 (2.6) | 3 (4.3) | 5 (3.4) |
| Carcinoma | 2 (2.6) | 3 (4.3) | 5 (3.4) |
| Sarcoma | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Other diseases* | 2 (2.6) | 3 (4.3) | 5 (3.4) |
ALL indicates acute lymphoblastic leukemia; ANLL, acute nonlymphocytic leukemia; AML, acute myeloid leukemia; HCL, hairy cell leukemia; CML, chronic myelogenous leukemia; CLL, chronic lymphocytic leukemia; and CMML, chronic myelomonocytic leukemia.
Other diseases included 5 patients with nonmalignant disorders undergoing stem cell transplantation.